Article(id=1329875867427254993, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1329875814855848930, articleNumber=null, orderNo=null, doi=10.16522/j.cnki.cjph.2024.11.002, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1712073600000, receivedDateStr=2024-04-03, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794996714693, onlineDateStr=2026-11-18, pubDate=1731168000000, pubDateStr=2024-11-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794996714693, onlineIssueDateStr=2026-11-18, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794996714693, creator=13701087609, updateTime=1794996714693, updator=13701087609, issue=Issue{id=1329875814855848930, tenantId=1146029695717560320, journalId=1319690259887390882, year='2024', volume='55', issue='11', pageStart='1449', pageEnd='1602', issueExtLink='null', onlineDate='null', pubDate='1731168000000', pubDateStr='2024-11-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794996702159, creator='13701087609', updateTime=1794996702159, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext=null, issueFiles=null, downloadFileDto=null}, startPage=1467, endPage=1476, ext={EN=ArticleExt(id=1329875867620192978, articleId=1329875867427254993, tenantId=1146029695717560320, journalId=1319690259887390882, language=EN, title=Research Progress on Proteolysis Targeting Chimeras, columnId=1327671134809600231, journalTitle=Chinese Journal of Pharmaceuticals, columnName=Review, runingTitle=null, highlight=null, articleAbstract=

Traditional small molecule kinase inhibitor drugs face numerous challenges, such as the propensity for drug resistance and the problem that some targets are undruggable. The proteolysis targeting chimera(PROTAC) technology utilizes the inherent ubiquitin-proteasome system in cells to achieve the degradation of proteins of interest(POI) for treating diseases, which can avoid the limitations of undruggable targets and drug resistance. Therefore, the PROTAC technology is expected to overcome the limitations of small molecule inhibitors. At present, some PROTACs have entered the clinical trial stage and are expected to become potential treatment methods for many diseases. This review introduces the biological mechanism, technical advantages, molecular design and clinical application prospects of PROTAC, hoping to provide a reference for its drug development and clinical application.

, authors=Hengyuan MA1, 2, Zhiqiang KE3, Zhengding SU1, *, authorsList=Hengyuan MA, Zhiqiang KE, Zhengding SU, authorCompany=null, correspAuthors=Zhengding SU, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329875867926377171, articleId=1329875867427254993, tenantId=1146029695717560320, journalId=1319690259887390882, language=CN, title=蛋白降解靶向嵌合体的研究进展, columnId=1327671135019315436, journalTitle=中国医药工业杂志, columnName=综述, runingTitle=null, highlight=null, articleAbstract=

传统的小分子激酶抑制剂药物面临着诸多挑战,如易产生耐药性和部分靶点不可成药的问题。蛋白降解靶向嵌合体(PROTAC)技术利用细胞内固有的泛素-蛋白酶体系统,实现对靶蛋白(POI)的降解以治疗疾病,可避免靶点不可成药和耐药性的限制,有望克服小分子抑制剂的局限。目前多款PROTAC已进入临床试验阶段,成为许多疾病潜在的治疗方式。文章综述了PROTAC的生物学机制、技术优势、分子设计及其临床应用前景,以期为其药物开发与临床应用提供参考。

, authors=马恒元1, 2, 柯志强3, 苏正定1, *, authorsList=马恒元, 柯志强, 苏正定, authorCompany=null, correspAuthors=苏正定, authorNote=

马恒元(1987—),男,硕士研究生,专业方向:生物与医药。

, correspAuthorsNote=
苏正定(1965—),男,教授,博士生导师,从事细胞信号转导机制、抗癌靶向药物设计、抗2型糖尿病口服GLP-1R激动剂设计及甾体药物合成生物学的研究。E-mail:
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=SntQH99830aM0y9R4gEE8A==, magXml=NByDV4b65I/JTRHs0L1GzA==, pdfUrl=null, pdf=4ukW0WiAK4JUdSkeBitRCA==, pdfFileSize=3043482, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=acfXJrT7/QCUygWprP9J7A==, mapNumber=null, fund=null)}, authors=[Author(id=1329875868450665182, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329875868521968353, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, authorId=1329875868450665182, language=EN, stringName=Hengyuan MA, firstName=Hengyuan, middleName=null, lastName=MA, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Hubei University of Technology, Wuhan 430068
2.Jiangsu Hengrui Pharmaceuticals Co., Ltd., Lianyungang 222000, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329875868601660130, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, authorId=1329875868450665182, language=CN, stringName=马恒元, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.湖北工业大学工业发酵省部共建协同创新中心,湖北 武汉 430068
2.江苏恒瑞医药股份有限公司,江苏 连云港 222000, bio={"content":"

马恒元(1987—),男,硕士研究生,专业方向:生物与医药。

"}, bioImg=null, bioContent=

马恒元(1987—),男,硕士研究生,专业方向:生物与医药。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329875868165452500, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, xref=1., ext=[AuthorCompanyExt(id=1329875868173841109, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, companyId=1329875868165452500, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Hubei University of Technology, Wuhan 430068), AuthorCompanyExt(id=1329875868182229718, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, companyId=1329875868165452500, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.湖北工业大学工业发酵省部共建协同创新中心,湖北 武汉 430068)]), AuthorCompany(id=1329875868266115799, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, xref=2., ext=[AuthorCompanyExt(id=1329875868278698712, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, companyId=1329875868266115799, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Jiangsu Hengrui Pharmaceuticals Co., Ltd., Lianyungang 222000), AuthorCompanyExt(id=1329875868287087321, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, companyId=1329875868266115799, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.江苏恒瑞医药股份有限公司,江苏 连云港 222000)])]), Author(id=1329875868664574692, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329875868761043686, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, authorId=1329875868664574692, language=EN, stringName=Zhiqiang KE, firstName=Zhiqiang, middleName=null, lastName=KE, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, address=3.Hubei Key Lab. of Diabetes and Angiopathy, Xianning Medical College, Hubei University of Science and Technology, Xianning 437100, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329875868840735463, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, authorId=1329875868664574692, language=CN, stringName=柯志强, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, address=3.湖北科技学院咸宁医学院,糖尿病心脑血管病变湖北省重点实验室,湖北 咸宁 437100, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329875868370973402, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, xref=3., ext=[AuthorCompanyExt(id=1329875868379362011, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, companyId=1329875868370973402, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.Hubei Key Lab. of Diabetes and Angiopathy, Xianning Medical College, Hubei University of Science and Technology, Xianning 437100), AuthorCompanyExt(id=1329875868387750620, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, companyId=1329875868370973402, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.湖北科技学院咸宁医学院,糖尿病心脑血管病变湖北省重点实验室,湖北 咸宁 437100)])]), Author(id=1329875868916232937, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=zhengdingsu@hbut.edu.cn, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329875869008507627, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, authorId=1329875868916232937, language=EN, stringName=Zhengding SU, firstName=Zhengding, middleName=null, lastName=SU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Hubei University of Technology, Wuhan 430068, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329875869075616492, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, authorId=1329875868916232937, language=CN, stringName=苏正定, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.湖北工业大学工业发酵省部共建协同创新中心,湖北 武汉 430068, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329875868165452500, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, xref=1., ext=[AuthorCompanyExt(id=1329875868173841109, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, companyId=1329875868165452500, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Hubei University of Technology, Wuhan 430068), AuthorCompanyExt(id=1329875868182229718, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, companyId=1329875868165452500, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.湖北工业大学工业发酵省部共建协同创新中心,湖北 武汉 430068)])])], keywords=[Keyword(id=1329875869155308269, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, language=EN, orderNo=1, keyword=undruggable target), Keyword(id=1329875869218222830, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, language=EN, orderNo=2, keyword=ubiquitin-proteasome system), Keyword(id=1329875869281137391, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, language=EN, orderNo=3, keyword=proteolysis targeting chimera), Keyword(id=1329875869348246256, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, language=EN, orderNo=4, keyword=clinical trial), Keyword(id=1329875871265043185, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, language=EN, orderNo=5, keyword=research progress), Keyword(id=1329875871344734962, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, language=CN, orderNo=1, keyword=不可成药靶点), Keyword(id=1329875871420232435, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, language=CN, orderNo=2, keyword=泛素-蛋白酶体系统), Keyword(id=1329875871504118516, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, language=CN, orderNo=3, keyword=蛋白降解靶向嵌合体), Keyword(id=1329875871562838773, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, language=CN, orderNo=4, keyword=临床试验), Keyword(id=1329875871642530550, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, language=CN, orderNo=5, keyword=研究进展)], refs=[Reference(id=1329875871734805239, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=CHITI F, DOBSON C M.Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade [J].Annu Rev Biochem, 2017, 86: 27-68., articleTitle=null, refAbstract=null), Reference(id=1329875871793525496, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=ATTWOOD M M, FABBRO D, SOKOLOV A V, et al.Trends in kinase drug discovery: targets, indications and inhibitor design [J].Nat Rev Drug Discov, 2021, 20(11): 839-861., articleTitle=null, refAbstract=null), Reference(id=1329875871869022969, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=COHEN P, CROSS D, JÄNNE P A.Kinase drug discovery 20 years after imatinib: progress and future directions [J].Nat Rev Drug Discov, 2021, 20(7): 551-569., articleTitle=null, refAbstract=null), Reference(id=1329875871944520442, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=ROSKOSKI R Jr.Properties of FDA-approved small molecule protein kinase inhibitors: a 2023 update [J].Pharmacol Res, 2023, 187: 106552., articleTitle=null, refAbstract=null), Reference(id=1329875872011629307, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=HENLEY M J, KOEHLER A N.Advances in targeting‘undruggable’ transcription factors with small molecules [J].Nat Rev Drug Discov, 2021, 20(9): 669-688., articleTitle=null, refAbstract=null), Reference(id=1329875872082932476, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=MAKLEY L N, GESTWICKI J E.Expanding the number of ‘druggable’ targets: non-enzymes and protein-protein interactions [J].Chem Biol Drug Des, 2013, 81(1): 22-32., articleTitle=null, refAbstract=null), Reference(id=1329875872145847037, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHANG Z Y.Drugging the undruggable: therapeutic potential of targeting protein tyrosine phosphatases [J].Acc Chem Res, 2017, 50(1): 122-129., articleTitle=null, refAbstract=null), Reference(id=1329875872204567294, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=FEDOROV Y, ANDERSON E M, BIRMINGHAM A, et al.Off-target effects by siRNA can induce toxic phenotype [J].RNA, 2006, 12: 1188-1196., articleTitle=null, refAbstract=null), Reference(id=1329875872271676159, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=HUSSAIN W, MAHMOOD T, HUSSAIN J, et al.CRISPR/Cas system: a game changing genome editing technology, to treat human genetic diseases [J].Gene, 2019, 685: 70-75., articleTitle=null, refAbstract=null), Reference(id=1329875872342979328, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHAO L, ZHAO J, ZHONG K, et al.Targeted protein degradation: mechanisms, strategies and application [J].Signal Transduct Target Ther, 2022, 7(1): 113., articleTitle=null, refAbstract=null), Reference(id=1329875872405893889, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=CHIRNOMAS D, HORNBERGER K R, CREWS C M.Protein degraders enter the clinic - a new approach to cancer therapy [J].Nat Rev Clin Oncol, 2023, 20(4): 265-278., articleTitle=null, refAbstract=null), Reference(id=1329875872481391362, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=CIECHANOVER A.Proteolysis: from the lysosome to ubiquitin and the proteasome [J].Nat Rev Mol Cell Biol, 2005, 6(1): 79-87., articleTitle=null, refAbstract=null), Reference(id=1329875872552694531, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=SHEN M, SCHMITT S, BUAC D, et al.Targeting the ubiquitin-proteasome system for cancer therapy [J].Expert Opin Ther Targets, 2013, 17(9): 1091-1108., articleTitle=null, refAbstract=null), Reference(id=1329875872628192004, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=NEKLESA T K, WINKLER J D, CREWS C M.Targeted protein degradation by PROTACs [J].Pharmacol Ther, 2017, 174: 138-144., articleTitle=null, refAbstract=null), Reference(id=1329875872703689477, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=LIU Z, HU M X, YANG Y, et al.An overview of PROTACs: a promising drug discovery paradigm [J].Mol Biomed, 2022, 3(1): 46., articleTitle=null, refAbstract=null), Reference(id=1329875872766604038, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=MAPLE H J, CLAYDEN N, BARON A, et al.Developing degraders: principles and perspectives on design and chemical space [J].Medchemcomm, 2019, 10(10): 1755-1764., articleTitle=null, refAbstract=null), Reference(id=1329875872829518599, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=BURSLEM G M, SMITH B E, LAI A C, et al.The advantages of targeted protein degradation over inhibition: an RTK case study [J].Cell Chem Biol, 2018, 25(1): 67-77., articleTitle=null, refAbstract=null), Reference(id=1329875872896627464, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=CREW A P, RAINA K, DONG H Q, et al.Identification and characterization of von Hippel-Lindau-recruiting proteolysis targeting chimeras(PROTACs) of tank-binding kinase 1 [J].J Med Chem, 2018, 61(2): 583-598., articleTitle=null, refAbstract=null), Reference(id=1329875872963736329, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=CAO C G, HE M, WANG L G, et al.Chemistries of bifunctional PROTAC degraders [J].Chem Soc Rev, 2022, 51(16): 7066-7114., articleTitle=null, refAbstract=null), Reference(id=1329875873056011018, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=BONDESON D P, SMITH B E, BURSLEM G M, et al.Lessons in PROTAC design from selective degradation with a promiscuous warhead [J].Cell Chem Biol, 2018, 25: 78-87., articleTitle=null, refAbstract=null), Reference(id=1329875873135702795, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=SCHAPIRA M, CALABRESE M F, BULLOCK A N, et al.Targeted protein degradation: expanding the toolbox [J].Nat Rev Drug Discov, 2019, 18(22): 949-963., articleTitle=null, refAbstract=null), Reference(id=1329875873198617356, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=SMITH B E, WANG S L, JAIME-FIGUEROA S, et al.Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase [J].Nat Commun, 2019, 10(1): 131., articleTitle=null, refAbstract=null), Reference(id=1329875873274114829, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=刘润哲,宋俊科,刘艾林,等.人工智能在基于配体和受体结构的药物筛选中的应用进展[J].药学学报,2021,56(8):2136-2145., articleTitle=null, refAbstract=null), Reference(id=1329875873345417998, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=ABRAMSON J, ADLER J, DUNGER J, et al.Accurate structure prediction of biomolecular interactions with AlphaFold 3 [J].Nature, 2024, 630(8016): 493-500., articleTitle=null, refAbstract=null), Reference(id=1329875873416721167, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHENG S J, TAN Y H, WANG Z Y, et al.Accelerated rational PROTAC design via deep learning and molecular simulations [J].Nat Mach Intell, 2022, 4: 739-748., articleTitle=null, refAbstract=null), Reference(id=1329875873488024336, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=张立.基于深度学习的计算药物发现研究[D].徐州:中国矿业大学博士学位论文,2023., articleTitle=null, refAbstract=null), Reference(id=1329875873550938897, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=WANG C, ZHANG Y J, YANG S B, et al.Recent advances of PROTACs technology in neurodegenerative diseases [J].Arabian J Chem, 2023, 16(9): 105015., articleTitle=null, refAbstract=null), Reference(id=1329875873626436370, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=HE Y D, XU W D, XIAO Y T, et al.Targeting signaling pathways in prostate cancer: mechanisms and clinical trials[J].Signal Transduct Target Ther, 2022, 7(1): 198., articleTitle=null, refAbstract=null), Reference(id=1329875873689350931, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=WEN S M, QUAN C Y, JIANG N, et al.What is the next generation therapeutic strategy for castration-resistant prostate cancer [J].Asian J Androl, 2015, 17(2): 223-224., articleTitle=null, refAbstract=null), Reference(id=1329875873752265492, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=ANTONARAKIS E S, LU C X, WANG H, et al.AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer[J].N Engl J Med, 2014, 371(11): 1028-1038., articleTitle=null, refAbstract=null), Reference(id=1329875873815180053, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=GAO X, BURRIS III H A, VUKY J, et al.Phase 1/2 study of ARV-110, an androgen receptor(AR) PROTAC degrader, in metastatic castration-resistant prostate cancer(mCRPC) [J].J Clin Oncol, 2022, 40(6_Suppl): 17., articleTitle=null, refAbstract=null), Reference(id=1329875873886483222, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=钱浩,周伟澄,蔡正艳.蛋白降解靶向嵌合体药物的研究进展[J].中国医药工业杂志,2024,55(6):750-760, articleTitle=null, refAbstract=null), Reference(id=1329875873949397783, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=PETRYLAK D P, STEWART T F, GAO X, et al.A phase 2 expansion study of ARV-766, a PROTAC androgen receptor(AR) degrader, in metastatic castration-resistant prostate cancer(mCRPC) [J].J Clin Oncol, 2023, 41(6_Suppl): TPS290., articleTitle=null, refAbstract=null), Reference(id=1329875874020700952, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=PETRYLAK D P, MCKEAN M, LANG J M, et al.ARV-766, a proteolysis targeting chimera(PROTAC) androgen receptor(AR) degrader, in metastatic castration-resistant prostate cancer(mCRPC): initial results of a phase 1/2 study[J].J Clin Oncol, 2024, 42(6_Suppl): 5011., articleTitle=null, refAbstract=null), Reference(id=1329875874083615513, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=SCHOTT A F, HURVITZ S, MA C, et al.Abstract GS3-03: GS3-03 ARV-471, a PROTAC® estrogen receptor(ER)degrader in advanced ER-positive/human epidermal growth factor receptor 2(HER2)-negative breast cancer: phase 2 expansion(VERITAC) of a phase 1/2 study [J].Cancer Res, 2023, 83(5_Suppl): GS3-03., articleTitle=null, refAbstract=null), Reference(id=1329875874146530074, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=GOUGH S M, FLANAGAN J J, TEH J, et al.Oral estrogen receptor PROTAC® vepdegestrant(ARV-471) is highly efficacious as monotherapy and in combination with CDK4/6 or PI3K/mTOR pathway inhibitors in preclinical ER+ breast cancer models [J].Clin Cancer Res, 2024, 30(16): 3549-3563., articleTitle=null, refAbstract=null), Reference(id=1329875874226221851, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=WINTER G E, BUCKLEY D L, PAULK J, et al.DRUG DEVELOPMENT.Phthalimide conjugation as a strategy for in vivo target protein degradation [J].Science, 2015, 348: 1376-1381., articleTitle=null, refAbstract=null), Reference(id=1329875874318496540, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=LU J, QIAN Y M, ALTIERI M, et al.Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4 [J].Chem Biol, 2015, 22(6): 755-763., articleTitle=null, refAbstract=null), Reference(id=1329875874385605405, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=QIN A C, JIN H, SONG Y, et al.The therapeutic effect of the BRD4-degrading PROTAC A1874 in human colon cancer cells [J].Cell Death Dis, 2020, 11(9): 805., articleTitle=null, refAbstract=null), Reference(id=1329875874469491486, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=PENG X P, HU Z H, ZENG L M, et al.Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies [J].Acta Pharm Sin B, 2024, 14(2): 533-578., articleTitle=null, refAbstract=null), Reference(id=1329875874540794655, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=WEN T Y, WANG J S, SHI Y K, et al.Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances [J].Leukemia, 2021, 35(2): 312-332., articleTitle=null, refAbstract=null), Reference(id=1329875874616292128, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=魏超,冉莹瑛,秦鹏霞,等.应对BTK突变所致耐药的分子设计策略[J].中国医药工业杂志,2021,52(8):987-998., articleTitle=null, refAbstract=null), Reference(id=1329875874700178209, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=SUN Y H, ZHAO X W, DING N, et al.PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies [J].Cell Res, 2018, 28(7): 779-781., articleTitle=null, refAbstract=null), Reference(id=1329875874758898466, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=SUN Y H, DING N, SONG Y Q, et al.Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas[J].Leukemia, 2019, 33(8): 2105-2110., articleTitle=null, refAbstract=null), Reference(id=1329875874834395939, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=MIHALIC J T, BRATHABAN N, BRAVO B, et al.Abstract 3423: NX-2127: a first-in-class clinical stage degrader of BTK and IKZF1/3 for the treatment of patients with B cell malignancies [J].Cancer Res, 2023, 83(7_Suppl): 3423., articleTitle=null, refAbstract=null), Reference(id=1329875874901504804, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=null, refType=null, unstructuredReference=ROBBINS D W, NOVISKI M A, TAN Y S, et al.Discovery and preclinical pharmacology of NX-2127, an orally bioavailable degrader of Bruton’s tyrosine kinase with immunomodulatory activity for the treatment of patients with B cell malignancies [J].J Med Chem, 2024, 67(4): 2321-2336., articleTitle=null, refAbstract=null), Reference(id=1329875874964419365, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[47], rfOrder=46, authorNames=null, journalName=null, refType=null, unstructuredReference=NOVISKI M A, BRATHABAN N, MUKERJI R, et al.Abstract 2850: NX-5948 promotes selective, sub-nanomolar degradation of inhibitor-resistant BTK mutants [J].Cancer Res, 2023, 83(7_Suppl): 2850., articleTitle=null, refAbstract=null), Reference(id=1329875875035722534, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[48], rfOrder=47, authorNames=null, journalName=null, refType=null, unstructuredReference=SEARLE E, FORCONI F, LINTON K, et al.Initial findings from a first-in-human phase 1a/b trial of NX-5948, a selective Bruton's tyrosine kinase(BTK) degrader, in patients with relapsed/refractory B cell malignancies [J].Blood, 2023, 142(Suppl 1): 4473., articleTitle=null, refAbstract=null), Reference(id=1329875875115414311, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[49], rfOrder=48, authorNames=null, journalName=null, refType=null, unstructuredReference=Nurix.Nurix therapeutics presents positive results from ongoing clinical trial of NX-5948 in patients with relapsed refractory chronic lymphocytic leukemia (CLL) at the European Hematology Association Congress(EHA2024) [EB/OL].(2024-06-16)[2024-06-17].https://ir.nurixtx.com/node/10196/pdf., articleTitle=null, refAbstract=null), Reference(id=1329875875169940264, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[50], rfOrder=49, authorNames=null, journalName=null, refType=null, unstructuredReference=Beigen.Preliminary efficacy and safety of the bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory CLL/SLL: results from the phase 1 BGB-16673-101 study [EB/OL].(2024-06-15)[2024-06-15].https://www.beigenemedical.com/CongressDocuments/Parrondo_BGB-16673-101_EHA_Presentation_2024.pdf., articleTitle=null, refAbstract=null), Reference(id=1329875875245437737, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[51], rfOrder=50, authorNames=null, journalName=null, refType=null, unstructuredReference=BOND M J, CHU L, NALAWANSHA D A, et al.Targeted degradation of oncogenic KRASG12C by VHL-recruiting PROTACs [J].ACS Cent Sci, 2020, 6(8): 1367-1375., articleTitle=null, refAbstract=null), Reference(id=1329875875312546602, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[52], rfOrder=51, authorNames=null, journalName=null, refType=null, unstructuredReference=NAGASHIMA T, YOSHINARI T, NISHIZONO Y, et al.Abstract 5735: novel KRAS G12D degrader ASP3082 demonstrates in vivo, dose-dependent KRAS degradation, KRAS pathway inhibition, and antitumor efficacy in multiple KRAS G12D-mutated cancer models [J].Cancer Res, 2023, 83(7_Suppl): 5735., articleTitle=null, refAbstract=null), Reference(id=1329875875379655467, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[53], rfOrder=52, authorNames=null, journalName=null, refType=null, unstructuredReference=MULLARD A.IRAK4 degrader to take on innate immunity[J].Nat Biotechnol, 2020, 38(11): 1221-1223., articleTitle=null, refAbstract=null), Reference(id=1329875875446764332, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[54], rfOrder=53, authorNames=null, journalName=null, refType=null, unstructuredReference=ACKERMAN L, ACLOQUE G, BACCHELLI S, et al.IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial [J].Nat Med, 29(12): 3127-3136., articleTitle=null, refAbstract=null), Reference(id=1329875875505484589, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[55], rfOrder=54, authorNames=null, journalName=null, refType=null, unstructuredReference=CONGDON E E, SIGURDSSON E M.Tau-targeting therapies for Alzheimer disease [J].Nat Rev Neurol, 2018, 14(7): 399-415., articleTitle=null, refAbstract=null), Reference(id=1329875875589370670, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[56], rfOrder=55, authorNames=null, journalName=null, refType=null, unstructuredReference=刘鹏,曹端源,罗金重,等.针对神经退行性疾病的蛋白水解靶向嵌合体研究进展[J].中国药学杂志,2023,58(19):1721-1730., articleTitle=null, refAbstract=null), Reference(id=1329875875652285231, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[57], rfOrder=56, authorNames=null, journalName=null, refType=null, unstructuredReference=HU Z Y, CHEN P H, LI W X, et al.Targeted dephosphorylation of Tau by phosphorylation targeting chimeras(PhosTACs) as a therapeutic modality [J].J Am Chem Soc, 2023, 145(7): 4045-4055., articleTitle=null, refAbstract=null), Reference(id=1329875875731977008, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[58], rfOrder=57, authorNames=null, journalName=null, refType=null, unstructuredReference=LIU J, CHEN H, MA L N, et al.Light-induced control of protein destruction by opto-PROTAC [J].Sci Adv, 2020, 6(8): eaay5154., articleTitle=null, refAbstract=null), Reference(id=1329875875954275121, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[59], rfOrder=58, authorNames=null, journalName=null, refType=null, unstructuredReference=CHEN H, LIU J, KANISKAN H Ü et al.Folate-guided protein degradation by immunomodulatory imide drug-based molecular glues and proteolysis targeting chimeras [J].J Med Chem, 2021, 64(16): 12273-12285., articleTitle=null, refAbstract=null), Reference(id=1329875876046549811, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[60], rfOrder=59, authorNames=null, journalName=null, refType=null, unstructuredReference=CHENG W Y, LI S S, WEN X Q, et al.Development of hypoxia-activated PROTAC exerting a more potent effect in tumor hypoxia than in normoxia [J].Chem Commun(Camb), 2021, 57(95): 12852-12855., articleTitle=null, refAbstract=null), Reference(id=1329875876113658676, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[61], rfOrder=60, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHANG C, HE S S, ZENG Z L, et al.Smart nano-PROTACs reprogram tumor microenvironment for activatable photo-metabolic cancer immunotherapy [J].Angew Chem Int Ed Engl, 2022, 61(8): e202114957., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1329875868165452500, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, xref=1., ext=[AuthorCompanyExt(id=1329875868173841109, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, companyId=1329875868165452500, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Hubei University of Technology, Wuhan 430068), AuthorCompanyExt(id=1329875868182229718, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, companyId=1329875868165452500, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.湖北工业大学工业发酵省部共建协同创新中心,湖北 武汉 430068)]), AuthorCompany(id=1329875868266115799, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, xref=2., ext=[AuthorCompanyExt(id=1329875868278698712, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, companyId=1329875868266115799, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Jiangsu Hengrui Pharmaceuticals Co., Ltd., Lianyungang 222000), AuthorCompanyExt(id=1329875868287087321, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, companyId=1329875868266115799, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.江苏恒瑞医药股份有限公司,江苏 连云港 222000)]), AuthorCompany(id=1329875868370973402, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, xref=3., ext=[AuthorCompanyExt(id=1329875868379362011, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, companyId=1329875868370973402, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.Hubei Key Lab. of Diabetes and Angiopathy, Xianning Medical College, Hubei University of Science and Technology, Xianning 437100), AuthorCompanyExt(id=1329875868387750620, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, companyId=1329875868370973402, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.湖北科技学院咸宁医学院,糖尿病心脑血管病变湖北省重点实验室,湖北 咸宁 437100)])], figs=null, attaches=null, journal=Journal(id=1319689822849302687, delFlag=0, nameCn=中国医药工业杂志, nameEn=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, issn=1001-8255, eissn=null, cn=31-1243/R, coden=ZYGZEA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=etiWDuwx2KO274LHw88KJA==, journalPrice=null, startedYear=null, abbrevIsoEn=Chinese Journal of Pharmaceuticals, journalRemark=null, publicationField=null, createdTime=1792568172420, updatedTime=1792747450744, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=Z, firstLetterEn=Z, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=etiWDuwx2KO274LHw88KJA==, picEn=ip9NF4dK57AmNrCiZ6hmdw==, jcr=null, cjcr=null, exts=[JournalExt(id=1320441770761105589, language=CN, name=中国医药工业杂志, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450771, updatedTime=1792747450771, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""}), JournalExt(id=1320441770819825846, language=EN, name=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450785, updatedTime=1792747450785, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""})], databaseList=null, tenantJournalId=1319690259887390882, websiteList=[Website(id=1319720771623174732, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/CN, language=CN, createTime=1792575551181, createBy=18614031015, updateTime=1792746040843, updateBy=18614031015, name=中国医药工业杂志-中文, tplId=1146099689490845704, title=中国医药工业杂志, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428487504769041, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=articleTextType, value=kx, createTime=1792982702375, updateTime=1792982702375, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487475408910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982702368, updateTime=1792982702368, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487538323476, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=grayFlag, value=0, createTime=1792982702383, updateTime=1792982702383, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487462825997, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982702365, updateTime=1792982702365, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487571877910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=minRunFlag, value=0, createTime=1792982702391, updateTime=1792982702391, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487496380432, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic, createTime=1792982702373, updateTime=1792982702373, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487563489301, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=silenceFlag, value=0, createTime=1792982702389, updateTime=1792982702389, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487483797519, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982702370, updateTime=1792982702370, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487517351954, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeColor, value=null, createTime=1792982702378, updateTime=1792982702378, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487525740563, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982702380, updateTime=1792982702380, creator=18614031015, updator=18614031015)]), Website(id=1319720771702866512, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/EN, language=EN, createTime=1792575551200, createBy=18614031015, updateTime=1792746037543, updateBy=18614031015, name=中国医药工业杂志-英文, tplId=1146101810881728533, title=Chinese Journal of Pharmaceuticals, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428509638111261, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=articleTextType, value=kx, createTime=1792982707652, updateTime=1792982707652, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509579391002, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982707638, updateTime=1792982707638, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509680054304, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=grayFlag, value=0, createTime=1792982707662, updateTime=1792982707662, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509566808089, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982707635, updateTime=1792982707635, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509701025826, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=minRunFlag, value=0, createTime=1792982707667, updateTime=1792982707667, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509629722652, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic, createTime=1792982707650, updateTime=1792982707650, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509688442913, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=silenceFlag, value=0, createTime=1792982707664, updateTime=1792982707664, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509587779611, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982707640, updateTime=1792982707640, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509663277086, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeColor, value=null, createTime=1792982707658, updateTime=1792982707658, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509671665695, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982707660, updateTime=1792982707660, creator=18614031015, updator=18614031015)])], journalTitle=中国医药工业杂志, weixinUrl=null, journalUrl=http://www.cjph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=Chinese Journal of Pharmaceuticals, journalPhotoCn=etiWDuwx2KO274LHw88KJA==, journalPhotoEn=ip9NF4dK57AmNrCiZ6hmdw==, journalFirstLetter=Z, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/10.16522/j.cnki.cjph.2024.11.002, detailUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/10.16522/j.cnki.cjph.2024.11.002, pdfUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/PDF/10.16522/j.cnki.cjph.2024.11.002, pdfUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/PDF/10.16522/j.cnki.cjph.2024.11.002, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1731168000000, fullTextJson=null, articleText=null, reference=null)
收藏切换
蛋白降解靶向嵌合体的研究进展
马恒元 1, 2 , 柯志强 3 , 苏正定 1, *
中国医药工业杂志 | 综述 2024,55(11): 1467-1476
收起
收藏切换
中国医药工业杂志 |综述 2024 , 55 (11) : 1467 -1476
蛋白降解靶向嵌合体的研究进展
全屏
[Author(id=1329875868450665182, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329875868521968353, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, authorId=1329875868450665182, language=EN, stringName=Hengyuan MA, firstName=Hengyuan, middleName=null, lastName=MA, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Hubei University of Technology, Wuhan 430068
2.Jiangsu Hengrui Pharmaceuticals Co., Ltd., Lianyungang 222000, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329875868601660130, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, authorId=1329875868450665182, language=CN, stringName=马恒元, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.湖北工业大学工业发酵省部共建协同创新中心,湖北 武汉 430068
2.江苏恒瑞医药股份有限公司,江苏 连云港 222000, bio={"content":"

马恒元(1987—),男,硕士研究生,专业方向:生物与医药。

"}, bioImg=null, bioContent=

马恒元(1987—),男,硕士研究生,专业方向:生物与医药。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329875868165452500, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, xref=1., ext=[AuthorCompanyExt(id=1329875868173841109, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, companyId=1329875868165452500, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Hubei University of Technology, Wuhan 430068), AuthorCompanyExt(id=1329875868182229718, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, companyId=1329875868165452500, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.湖北工业大学工业发酵省部共建协同创新中心,湖北 武汉 430068)]), AuthorCompany(id=1329875868266115799, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, xref=2., ext=[AuthorCompanyExt(id=1329875868278698712, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, companyId=1329875868266115799, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Jiangsu Hengrui Pharmaceuticals Co., Ltd., Lianyungang 222000), AuthorCompanyExt(id=1329875868287087321, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, companyId=1329875868266115799, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.江苏恒瑞医药股份有限公司,江苏 连云港 222000)])]), Author(id=1329875868664574692, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329875868761043686, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, authorId=1329875868664574692, language=EN, stringName=Zhiqiang KE, firstName=Zhiqiang, middleName=null, lastName=KE, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, address=3.Hubei Key Lab. of Diabetes and Angiopathy, Xianning Medical College, Hubei University of Science and Technology, Xianning 437100, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329875868840735463, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, authorId=1329875868664574692, language=CN, stringName=柯志强, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, address=3.湖北科技学院咸宁医学院,糖尿病心脑血管病变湖北省重点实验室,湖北 咸宁 437100, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329875868370973402, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, xref=3., ext=[AuthorCompanyExt(id=1329875868379362011, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, companyId=1329875868370973402, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.Hubei Key Lab. of Diabetes and Angiopathy, Xianning Medical College, Hubei University of Science and Technology, Xianning 437100), AuthorCompanyExt(id=1329875868387750620, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, companyId=1329875868370973402, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.湖北科技学院咸宁医学院,糖尿病心脑血管病变湖北省重点实验室,湖北 咸宁 437100)])]), Author(id=1329875868916232937, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=zhengdingsu@hbut.edu.cn, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329875869008507627, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, authorId=1329875868916232937, language=EN, stringName=Zhengding SU, firstName=Zhengding, middleName=null, lastName=SU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Hubei University of Technology, Wuhan 430068, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329875869075616492, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, authorId=1329875868916232937, language=CN, stringName=苏正定, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.湖北工业大学工业发酵省部共建协同创新中心,湖北 武汉 430068, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329875868165452500, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, xref=1., ext=[AuthorCompanyExt(id=1329875868173841109, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, companyId=1329875868165452500, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Hubei University of Technology, Wuhan 430068), AuthorCompanyExt(id=1329875868182229718, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329875867427254993, companyId=1329875868165452500, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.湖北工业大学工业发酵省部共建协同创新中心,湖北 武汉 430068)])])]
马恒元1, 2, 柯志强3, 苏正定1, *
作者信息
  • 1.湖北工业大学工业发酵省部共建协同创新中心,湖北 武汉 430068
  • 2.江苏恒瑞医药股份有限公司,江苏 连云港 222000
  • 3.湖北科技学院咸宁医学院,糖尿病心脑血管病变湖北省重点实验室,湖北 咸宁 437100
通讯作者:
苏正定(1965—),男,教授,博士生导师,从事细胞信号转导机制、抗癌靶向药物设计、抗2型糖尿病口服GLP-1R激动剂设计及甾体药物合成生物学的研究。E-mail:
作者简介:

马恒元(1987—),男,硕士研究生,专业方向:生物与医药。

Research Progress on Proteolysis Targeting Chimeras
Hengyuan MA1, 2, Zhiqiang KE3, Zhengding SU1, *
Affiliations
  • 1.Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Hubei University of Technology, Wuhan 430068
  • 2.Jiangsu Hengrui Pharmaceuticals Co., Ltd., Lianyungang 222000
  • 3.Hubei Key Lab. of Diabetes and Angiopathy, Xianning Medical College, Hubei University of Science and Technology, Xianning 437100
出版时间: 2024-11-10 doi: 10.16522/j.cnki.cjph.2024.11.002
文章导航
收藏切换

传统的小分子激酶抑制剂药物面临着诸多挑战,如易产生耐药性和部分靶点不可成药的问题。蛋白降解靶向嵌合体(PROTAC)技术利用细胞内固有的泛素-蛋白酶体系统,实现对靶蛋白(POI)的降解以治疗疾病,可避免靶点不可成药和耐药性的限制,有望克服小分子抑制剂的局限。目前多款PROTAC已进入临床试验阶段,成为许多疾病潜在的治疗方式。文章综述了PROTAC的生物学机制、技术优势、分子设计及其临床应用前景,以期为其药物开发与临床应用提供参考。

不可成药靶点  /  泛素-蛋白酶体系统  /  蛋白降解靶向嵌合体  /  临床试验  /  研究进展

Traditional small molecule kinase inhibitor drugs face numerous challenges, such as the propensity for drug resistance and the problem that some targets are undruggable. The proteolysis targeting chimera(PROTAC) technology utilizes the inherent ubiquitin-proteasome system in cells to achieve the degradation of proteins of interest(POI) for treating diseases, which can avoid the limitations of undruggable targets and drug resistance. Therefore, the PROTAC technology is expected to overcome the limitations of small molecule inhibitors. At present, some PROTACs have entered the clinical trial stage and are expected to become potential treatment methods for many diseases. This review introduces the biological mechanism, technical advantages, molecular design and clinical application prospects of PROTAC, hoping to provide a reference for its drug development and clinical application.

undruggable target  /  ubiquitin-proteasome system  /  proteolysis targeting chimera  /  clinical trial  /  research progress
马恒元, 柯志强, 苏正定. 蛋白降解靶向嵌合体的研究进展. 中国医药工业杂志, 2024 , 55 (11) : 1467 -1476 . DOI: 10.16522/j.cnki.cjph.2024.11.002
Hengyuan MA, Zhiqiang KE, Zhengding SU. Research Progress on Proteolysis Targeting Chimeras[J]. Chinese Journal of Pharmaceuticals, 2024 , 55 (11) : 1467 -1476 . DOI: 10.16522/j.cnki.cjph.2024.11.002

参考文献 引证文献
排序方式:
[1]
CHITI F, DOBSON C M.Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade [J].Annu Rev Biochem, 2017, 86: 27-68.
[2]
ATTWOOD M M, FABBRO D, SOKOLOV A V, et al.Trends in kinase drug discovery: targets, indications and inhibitor design [J].Nat Rev Drug Discov, 2021, 20(11): 839-861.
[3]
COHEN P, CROSS D, JÄNNE P A.Kinase drug discovery 20 years after imatinib: progress and future directions [J].Nat Rev Drug Discov, 2021, 20(7): 551-569.
[4]
ROSKOSKI R Jr.Properties of FDA-approved small molecule protein kinase inhibitors: a 2023 update [J].Pharmacol Res, 2023, 187: 106552.
[5]
HENLEY M J, KOEHLER A N.Advances in targeting‘undruggable’ transcription factors with small molecules [J].Nat Rev Drug Discov, 2021, 20(9): 669-688.
[6]
MAKLEY L N, GESTWICKI J E.Expanding the number of ‘druggable’ targets: non-enzymes and protein-protein interactions [J].Chem Biol Drug Des, 2013, 81(1): 22-32.
[7]
ZHANG Z Y.Drugging the undruggable: therapeutic potential of targeting protein tyrosine phosphatases [J].Acc Chem Res, 2017, 50(1): 122-129.
[8]
FEDOROV Y, ANDERSON E M, BIRMINGHAM A, et al.Off-target effects by siRNA can induce toxic phenotype [J].RNA, 2006, 12: 1188-1196.
[9]
HUSSAIN W, MAHMOOD T, HUSSAIN J, et al.CRISPR/Cas system: a game changing genome editing technology, to treat human genetic diseases [J].Gene, 2019, 685: 70-75.
[10]
ZHAO L, ZHAO J, ZHONG K, et al.Targeted protein degradation: mechanisms, strategies and application [J].Signal Transduct Target Ther, 2022, 7(1): 113.
[11]
CHIRNOMAS D, HORNBERGER K R, CREWS C M.Protein degraders enter the clinic - a new approach to cancer therapy [J].Nat Rev Clin Oncol, 2023, 20(4): 265-278.
[12]
CIECHANOVER A.Proteolysis: from the lysosome to ubiquitin and the proteasome [J].Nat Rev Mol Cell Biol, 2005, 6(1): 79-87.
[13]
SHEN M, SCHMITT S, BUAC D, et al.Targeting the ubiquitin-proteasome system for cancer therapy [J].Expert Opin Ther Targets, 2013, 17(9): 1091-1108.
[14]
NEKLESA T K, WINKLER J D, CREWS C M.Targeted protein degradation by PROTACs [J].Pharmacol Ther, 2017, 174: 138-144.
[15]
LIU Z, HU M X, YANG Y, et al.An overview of PROTACs: a promising drug discovery paradigm [J].Mol Biomed, 2022, 3(1): 46.
[16]
MAPLE H J, CLAYDEN N, BARON A, et al.Developing degraders: principles and perspectives on design and chemical space [J].Medchemcomm, 2019, 10(10): 1755-1764.
[17]
BURSLEM G M, SMITH B E, LAI A C, et al.The advantages of targeted protein degradation over inhibition: an RTK case study [J].Cell Chem Biol, 2018, 25(1): 67-77.
[18]
CREW A P, RAINA K, DONG H Q, et al.Identification and characterization of von Hippel-Lindau-recruiting proteolysis targeting chimeras(PROTACs) of tank-binding kinase 1 [J].J Med Chem, 2018, 61(2): 583-598.
[19]
CAO C G, HE M, WANG L G, et al.Chemistries of bifunctional PROTAC degraders [J].Chem Soc Rev, 2022, 51(16): 7066-7114.
[20]
BONDESON D P, SMITH B E, BURSLEM G M, et al.Lessons in PROTAC design from selective degradation with a promiscuous warhead [J].Cell Chem Biol, 2018, 25: 78-87.
[21]
SCHAPIRA M, CALABRESE M F, BULLOCK A N, et al.Targeted protein degradation: expanding the toolbox [J].Nat Rev Drug Discov, 2019, 18(22): 949-963.
[22]
SMITH B E, WANG S L, JAIME-FIGUEROA S, et al.Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase [J].Nat Commun, 2019, 10(1): 131.
[23]
刘润哲,宋俊科,刘艾林,等.人工智能在基于配体和受体结构的药物筛选中的应用进展[J].药学学报,2021,56(8):2136-2145.
[24]
ABRAMSON J, ADLER J, DUNGER J, et al.Accurate structure prediction of biomolecular interactions with AlphaFold 3 [J].Nature, 2024, 630(8016): 493-500.
[25]
ZHENG S J, TAN Y H, WANG Z Y, et al.Accelerated rational PROTAC design via deep learning and molecular simulations [J].Nat Mach Intell, 2022, 4: 739-748.
[26]
张立.基于深度学习的计算药物发现研究[D].徐州:中国矿业大学博士学位论文,2023.
[27]
WANG C, ZHANG Y J, YANG S B, et al.Recent advances of PROTACs technology in neurodegenerative diseases [J].Arabian J Chem, 2023, 16(9): 105015.
[28]
HE Y D, XU W D, XIAO Y T, et al.Targeting signaling pathways in prostate cancer: mechanisms and clinical trials[J].Signal Transduct Target Ther, 2022, 7(1): 198.
[29]
WEN S M, QUAN C Y, JIANG N, et al.What is the next generation therapeutic strategy for castration-resistant prostate cancer [J].Asian J Androl, 2015, 17(2): 223-224.
[30]
ANTONARAKIS E S, LU C X, WANG H, et al.AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer[J].N Engl J Med, 2014, 371(11): 1028-1038.
[31]
GAO X, BURRIS III H A, VUKY J, et al.Phase 1/2 study of ARV-110, an androgen receptor(AR) PROTAC degrader, in metastatic castration-resistant prostate cancer(mCRPC) [J].J Clin Oncol, 2022, 40(6_Suppl): 17.
[32]
钱浩,周伟澄,蔡正艳.蛋白降解靶向嵌合体药物的研究进展[J].中国医药工业杂志,2024,55(6):750-760
[33]
PETRYLAK D P, STEWART T F, GAO X, et al.A phase 2 expansion study of ARV-766, a PROTAC androgen receptor(AR) degrader, in metastatic castration-resistant prostate cancer(mCRPC) [J].J Clin Oncol, 2023, 41(6_Suppl): TPS290.
[34]
PETRYLAK D P, MCKEAN M, LANG J M, et al.ARV-766, a proteolysis targeting chimera(PROTAC) androgen receptor(AR) degrader, in metastatic castration-resistant prostate cancer(mCRPC): initial results of a phase 1/2 study[J].J Clin Oncol, 2024, 42(6_Suppl): 5011.
[35]
SCHOTT A F, HURVITZ S, MA C, et al.Abstract GS3-03: GS3-03 ARV-471, a PROTAC® estrogen receptor(ER)degrader in advanced ER-positive/human epidermal growth factor receptor 2(HER2)-negative breast cancer: phase 2 expansion(VERITAC) of a phase 1/2 study [J].Cancer Res, 2023, 83(5_Suppl): GS3-03.
[36]
GOUGH S M, FLANAGAN J J, TEH J, et al.Oral estrogen receptor PROTAC® vepdegestrant(ARV-471) is highly efficacious as monotherapy and in combination with CDK4/6 or PI3K/mTOR pathway inhibitors in preclinical ER+ breast cancer models [J].Clin Cancer Res, 2024, 30(16): 3549-3563.
[37]
WINTER G E, BUCKLEY D L, PAULK J, et al.DRUG DEVELOPMENT.Phthalimide conjugation as a strategy for in vivo target protein degradation [J].Science, 2015, 348: 1376-1381.
[38]
LU J, QIAN Y M, ALTIERI M, et al.Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4 [J].Chem Biol, 2015, 22(6): 755-763.
[39]
QIN A C, JIN H, SONG Y, et al.The therapeutic effect of the BRD4-degrading PROTAC A1874 in human colon cancer cells [J].Cell Death Dis, 2020, 11(9): 805.
[40]
PENG X P, HU Z H, ZENG L M, et al.Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies [J].Acta Pharm Sin B, 2024, 14(2): 533-578.
[41]
WEN T Y, WANG J S, SHI Y K, et al.Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances [J].Leukemia, 2021, 35(2): 312-332.
[42]
魏超,冉莹瑛,秦鹏霞,等.应对BTK突变所致耐药的分子设计策略[J].中国医药工业杂志,2021,52(8):987-998.
[43]
SUN Y H, ZHAO X W, DING N, et al.PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies [J].Cell Res, 2018, 28(7): 779-781.
[44]
SUN Y H, DING N, SONG Y Q, et al.Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas[J].Leukemia, 2019, 33(8): 2105-2110.
[45]
MIHALIC J T, BRATHABAN N, BRAVO B, et al.Abstract 3423: NX-2127: a first-in-class clinical stage degrader of BTK and IKZF1/3 for the treatment of patients with B cell malignancies [J].Cancer Res, 2023, 83(7_Suppl): 3423.
[46]
ROBBINS D W, NOVISKI M A, TAN Y S, et al.Discovery and preclinical pharmacology of NX-2127, an orally bioavailable degrader of Bruton’s tyrosine kinase with immunomodulatory activity for the treatment of patients with B cell malignancies [J].J Med Chem, 2024, 67(4): 2321-2336.
[47]
NOVISKI M A, BRATHABAN N, MUKERJI R, et al.Abstract 2850: NX-5948 promotes selective, sub-nanomolar degradation of inhibitor-resistant BTK mutants [J].Cancer Res, 2023, 83(7_Suppl): 2850.
[48]
SEARLE E, FORCONI F, LINTON K, et al.Initial findings from a first-in-human phase 1a/b trial of NX-5948, a selective Bruton's tyrosine kinase(BTK) degrader, in patients with relapsed/refractory B cell malignancies [J].Blood, 2023, 142(Suppl 1): 4473.
[49]
Nurix.Nurix therapeutics presents positive results from ongoing clinical trial of NX-5948 in patients with relapsed refractory chronic lymphocytic leukemia (CLL) at the European Hematology Association Congress(EHA2024) [EB/OL].(2024-06-16)[2024-06-17].https://ir.nurixtx.com/node/10196/pdf.
[50]
Beigen.Preliminary efficacy and safety of the bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory CLL/SLL: results from the phase 1 BGB-16673-101 study [EB/OL].(2024-06-15)[2024-06-15].https://www.beigenemedical.com/CongressDocuments/Parrondo_BGB-16673-101_EHA_Presentation_2024.pdf.
[51]
BOND M J, CHU L, NALAWANSHA D A, et al.Targeted degradation of oncogenic KRASG12C by VHL-recruiting PROTACs [J].ACS Cent Sci, 2020, 6(8): 1367-1375.
[52]
NAGASHIMA T, YOSHINARI T, NISHIZONO Y, et al.Abstract 5735: novel KRAS G12D degrader ASP3082 demonstrates in vivo, dose-dependent KRAS degradation, KRAS pathway inhibition, and antitumor efficacy in multiple KRAS G12D-mutated cancer models [J].Cancer Res, 2023, 83(7_Suppl): 5735.
[53]
MULLARD A.IRAK4 degrader to take on innate immunity[J].Nat Biotechnol, 2020, 38(11): 1221-1223.
[54]
ACKERMAN L, ACLOQUE G, BACCHELLI S, et al.IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial [J].Nat Med, 29(12): 3127-3136.
[55]
CONGDON E E, SIGURDSSON E M.Tau-targeting therapies for Alzheimer disease [J].Nat Rev Neurol, 2018, 14(7): 399-415.
[56]
刘鹏,曹端源,罗金重,等.针对神经退行性疾病的蛋白水解靶向嵌合体研究进展[J].中国药学杂志,2023,58(19):1721-1730.
[57]
HU Z Y, CHEN P H, LI W X, et al.Targeted dephosphorylation of Tau by phosphorylation targeting chimeras(PhosTACs) as a therapeutic modality [J].J Am Chem Soc, 2023, 145(7): 4045-4055.
[58]
LIU J, CHEN H, MA L N, et al.Light-induced control of protein destruction by opto-PROTAC [J].Sci Adv, 2020, 6(8): eaay5154.
[59]
CHEN H, LIU J, KANISKAN H Ü et al.Folate-guided protein degradation by immunomodulatory imide drug-based molecular glues and proteolysis targeting chimeras [J].J Med Chem, 2021, 64(16): 12273-12285.
[60]
CHENG W Y, LI S S, WEN X Q, et al.Development of hypoxia-activated PROTAC exerting a more potent effect in tumor hypoxia than in normoxia [J].Chem Commun(Camb), 2021, 57(95): 12852-12855.
[61]
ZHANG C, HE S S, ZENG Z L, et al.Smart nano-PROTACs reprogram tumor microenvironment for activatable photo-metabolic cancer immunotherapy [J].Angew Chem Int Ed Engl, 2022, 61(8): e202114957.
2024年第55卷第11期
28
7
0
引用本文
BibTeX
文章信息
doi: 10.16522/j.cnki.cjph.2024.11.002
  • 接收时间:2024-04-03
  • 首发时间:2026-11-18
  • 出版时间:2024-11-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2024-04-03
基金
作者信息
    1.湖北工业大学工业发酵省部共建协同创新中心,湖北 武汉 430068
    2.江苏恒瑞医药股份有限公司,江苏 连云港 222000
    3.湖北科技学院咸宁医学院,糖尿病心脑血管病变湖北省重点实验室,湖北 咸宁 437100

通讯作者:

苏正定(1965—),男,教授,博士生导师,从事细胞信号转导机制、抗癌靶向药物设计、抗2型糖尿病口服GLP-1R激动剂设计及甾体药物合成生物学的研究。E-mail:
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/zgyygy/CN/10.16522/j.cnki.cjph.2024.11.002
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏